Combination therapy for hepatitis B.
Level V
Where this comes from
- Record sourced from PubMed, PMID 11889057.
- Also identified by PMC identifier 1773159.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatitis B virus is a major cause of morbidity and mortality worldwide. Effective therapies were first introduced in the mid-1980s but frequent and sometimes severe side effects limit their use. Combination therapy represents the future of treatment for chronic hepatitis B, probably consisting of two or more nucleoside analogues although interferon may form part of some combinations. New drugs acting by different antiviral mechanisms may be particularly potent in combination.
Medical subject headings
- 2-Aminopurine
- Antiviral Agents
- Hepatitis B, Chronic